The Role of SGLT-2 Inhibitors in Heart Failure: A Roundtable Discussion

The American Journal of Managed Care® recently hosted a Peer Exchange that featured discussion among a panel of expert cardiologists and managed care decision makers regarding how cardiovascular outcome trial results are impacting the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure and how these drugs are shaping heart failure outcomes for patients. Panelists were Nihar R. Desai, MD, MPH, assistant professor of medicine in the cardiovascular medicine section of the Yale School of Medicine and investigator in the Center for Outcomes Research and Evaluation in New Haven, Connecticut; Jaime Murillo, MD, national senior director of cardiology at UnitedHealthcare in Fort Lauderdale, Florida; and Steven Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Cleveland, Ohio. The moderator was Neil B. Minkoff, MD, chief medical officer of Coeus Consulting Group in Sudbury, Massachusetts.

An editor from The American Journal of Managed Care® spoke with Darren K. McGuire, MD, MHSc, to discuss the impact of the results of cardiovascular outcome trials on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure in real-world clinical practice. McGuire is professor of medicine, director of the cardiology clinical trials unit, and director of the Parkland Hospital and Health System outpatient cardiology clinics at the University of Texas Southwestern Medical Center in Dallas.